Summary of Study ST004406
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002785. The data can be accessed directly via it's Project DOI: 10.21228/M8P25P This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST004406 |
| Study Title | Effects of a Complex Probiotic Intervention on Serum Metabolism and Tumor-Bearing Intestinal Segment Metabolism in FOLFOX Chemotherapy-Treated Mice with Colorectal Cancer |
| Study Summary | An AOM/DSS-induced inflammation-associated colorectal cancer mouse model was established to investigate the metabolic changes in FOLFOX chemotherapy with and without combined probiotic intervention. For the azoxymethane plus dextran sulfate sodium (AOM/DSS) model, 8-week-old female BALB/c mice were intraperitoneally injected with 10 mg/kg AOM (Sigma-Aldrich, Saint Louis, USA), followed by three cycles of DSS (MP Biomedicals, Ohio, USA) to mimic colitis-associated colorectal cancer (CAC). For each cycle, the mice were given free access to drinking water supplemented with 2% DSS for 1 week, followed by 2 weeks of regular water. FOLFOX treatment was used as described in 10.3390/nu15051117. Following a one-week intervention with composite probiotics or vehicle, oxaliplatin (1 mg/kg) was administered intraperitoneally, followed by daily intraperitoneal injections of 5-fluorouracil (50 mg/kg) and calcium folinate (10 mg/kg) for 5 days. All solutions were freshly prepared in sterile saline before administration. The control group received an equivalent volume of saline via intraperitoneal injection. On the day of oxaliplatin injection, loperamide (0.2 mg/day) was administered via oral gavage to the designated mice, according to the experimental protocol.The tissue and serum samples for this test were collected one day after completion of the FOLFOX regimen. Compared with the CAC-F group, the CAC-FPL group displayed 62 upregulated and 36 downregulated metabolites in tumor tissues, along with 181 upregulated and 149 downregulated serum metabolites. Pathway analysis revealed significant enrichment of nicotinate and nicotinamide metabolism, suggesting that nicotinamide metabolism may be a key mechanism by which composite probiotics enhance CAC-FOLFOX prognosis. Probiotics counteract FOLFOX-induced NAD⁺ depletion via downregulating NNMT to reduce nicotinamide loss and reshaping microbiota to enhance nicotinic acid production. |
| Institute | Lanzhou University |
| Department | School of Life Sciences |
| Laboratory | Probiotics and Life Health Institute |
| Last Name | Chen |
| First Name | Hu |
| Address | Lanzhou University, Lanzhou City, Gansu Province, China |
| chenhu21@lzu.edu.cn | |
| Phone | 13732910293 |
| Submit Date | 2025-11-14 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzXML |
| Analysis Type Detail | LC-MS |
| Release Date | 2025-12-19 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR002785 |
| Project DOI: | doi: 10.21228/M8P25P |
| Project Title: | Effects of a Complex Probiotic Intervention on Serum Metabolism and Tumor-Bearing Intestinal Segment Metabolism in FOLFOX Chemotherapy-Treated Mice with Colorectal Cancer |
| Project Summary: | An AOM/DSS-induced inflammation-associated colorectal cancer mouse model was established to investigate the metabolic changes in FOLFOX chemotherapy with and without complex probiotic intervention. |
| Institute: | Lanzhou University |
| Department: | School of Life Sciences |
| Laboratory: | Probiotics and Life Health Institute |
| Last Name: | Chen |
| First Name: | Hu |
| Address: | Lanzhou University, Lanzhou City, Gansu Province, China, lanzhou, Gansu, 730000, China |
| Email: | chenhu21@lzu.edu.cn |
| Phone: | 13732910293 |
Subject:
| Subject ID: | SU004565 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
| Gender: | Female |
| Animal Animal Supplier: | Laboratory Animal Center, Lanzhou University |
| Animal Housing: | Five mice were housed in individually ventilated cages. |
| Animal Light Cycle: | 12 h light/dark cycle |
| Animal Feed: | standard diet ad libitum |
| Animal Water: | Provide a 2% DSS solution or normal drinking water on a regular basis. |
| Animal Inclusion Criteria: | eight-week-old BALB/c |
Factors:
Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Sample source | Treatment |
|---|---|---|---|
| SA521341 | B1T | colonic tissue | AOM/DSS |
| SA521342 | B6T | colonic tissue | AOM/DSS |
| SA521343 | B5T | colonic tissue | AOM/DSS |
| SA521344 | B4T | colonic tissue | AOM/DSS |
| SA521345 | B3T | colonic tissue | AOM/DSS |
| SA521346 | B2T | colonic tissue | AOM/DSS |
| SA521347 | F2T | colonic tissue | AOM/DSS+FOLFOX |
| SA521348 | F1T | colonic tissue | AOM/DSS+FOLFOX |
| SA521349 | F3T | colonic tissue | AOM/DSS+FOLFOX |
| SA521350 | F4T | colonic tissue | AOM/DSS+FOLFOX |
| SA521351 | F5T | colonic tissue | AOM/DSS+FOLFOX |
| SA521352 | F6T | colonic tissue | AOM/DSS+FOLFOX |
| SA521353 | G1T | colonic tissue | AOM/DSS+FOLFOX+Probiotics |
| SA521354 | G5T | colonic tissue | AOM/DSS+FOLFOX+Probiotics |
| SA521355 | G4T | colonic tissue | AOM/DSS+FOLFOX+Probiotics |
| SA521356 | G3T | colonic tissue | AOM/DSS+FOLFOX+Probiotics |
| SA521357 | G6T | colonic tissue | AOM/DSS+FOLFOX+Probiotics |
| SA521358 | G2T | colonic tissue | AOM/DSS+FOLFOX+Probiotics |
| SA521359 | H1T | colonic tissue | AOM/DSS+FOLFOX+Probiotics+Loperamide |
| SA521360 | H6T | colonic tissue | AOM/DSS+FOLFOX+Probiotics+Loperamide |
| SA521361 | H4T | colonic tissue | AOM/DSS+FOLFOX+Probiotics+Loperamide |
| SA521362 | H3T | colonic tissue | AOM/DSS+FOLFOX+Probiotics+Loperamide |
| SA521363 | H2T | colonic tissue | AOM/DSS+FOLFOX+Probiotics+Loperamide |
| SA521364 | H5T | colonic tissue | AOM/DSS+FOLFOX+Probiotics+Loperamide |
| SA521365 | A2T | colonic tissue | Control |
| SA521366 | A1T | colonic tissue | Control |
| SA521367 | A3T | colonic tissue | Control |
| SA521368 | A4T | colonic tissue | Control |
| SA521369 | A5T | colonic tissue | Control |
| SA521370 | A6T | colonic tissue | Control |
| SA521371 | B6S | serum | AOM/DSS |
| SA521372 | B1S | serum | AOM/DSS |
| SA521373 | B4S | serum | AOM/DSS |
| SA521374 | B3S | serum | AOM/DSS |
| SA521375 | B5S | serum | AOM/DSS |
| SA521376 | B2S | serum | AOM/DSS |
| SA521377 | F1S | serum | AOM/DSS+FOLFOX |
| SA521378 | F2S | serum | AOM/DSS+FOLFOX |
| SA521379 | F3S | serum | AOM/DSS+FOLFOX |
| SA521380 | F4S | serum | AOM/DSS+FOLFOX |
| SA521381 | F5S | serum | AOM/DSS+FOLFOX |
| SA521382 | F6S | serum | AOM/DSS+FOLFOX |
| SA521383 | G3S | serum | AOM/DSS+FOLFOX+Probiotics |
| SA521384 | G6S | serum | AOM/DSS+FOLFOX+Probiotics |
| SA521385 | G5S | serum | AOM/DSS+FOLFOX+Probiotics |
| SA521386 | G4S | serum | AOM/DSS+FOLFOX+Probiotics |
| SA521387 | G2S | serum | AOM/DSS+FOLFOX+Probiotics |
| SA521388 | G1S | serum | AOM/DSS+FOLFOX+Probiotics |
| SA521389 | H2S | serum | AOM/DSS+FOLFOX+Probiotics+Loperamide |
| SA521390 | H4S | serum | AOM/DSS+FOLFOX+Probiotics+Loperamide |
| SA521391 | H3S | serum | AOM/DSS+FOLFOX+Probiotics+Loperamide |
| SA521392 | H5S | serum | AOM/DSS+FOLFOX+Probiotics+Loperamide |
| SA521393 | H6S | serum | AOM/DSS+FOLFOX+Probiotics+Loperamide |
| SA521394 | H1S | serum | AOM/DSS+FOLFOX+Probiotics+Loperamide |
| SA521395 | A6S | serum | Control |
| SA521396 | A5S | serum | Control |
| SA521397 | A2S | serum | Control |
| SA521398 | A3S | serum | Control |
| SA521399 | A4S | serum | Control |
| SA521400 | A1S | serum | Control |
| Showing results 1 to 60 of 60 |
Collection:
| Collection ID: | CO004558 |
| Collection Summary: | Blood and colon tissue were collected from mice immediately after euthanasia. Serum was obtained by centrifuging the blood after it had sufficiently settled. Colon tissue was identified by personnel with specialized anatomical expertise, who excised tumor-bearing intestinal segments. These segments were rinsed with pre-chilled PBS buffer and rapidly frozen in liquid nitrogen for subsequent analysis. |
| Sample Type: | serum and colonic tissue |
| Volumeoramount Collected: | 100 μL and 200 mg |
| Storage Conditions: | -80℃ |
| Collection Tube Temp: | 4℃ |
Treatment:
| Treatment ID: | TR004574 |
| Treatment Summary: | For the azoxymethane plus dextran sulfate sodium (AOM/DSS) model, 8-week-old female BALB/c mice were intraperitoneally injected with 10 mg/kg AOM (Sigma-Aldrich, Saint Louis, USA), followed by three cycles of DSS (MP Biomedicals, Ohio, USA) to mimic colitis-associated colorectal cancer (CAC). For each cycle, the mice were given free access to drinking water supplemented with 2% DSS for 1 week, followed by 2 weeks of regular water. FOLFOX treatment was consistently applied in FOLFOX-induced injury, AOM/DSS-induced CAC, and MC38 tumor models. Following a one-week intervention with composite probiotics or vehicle, oxaliplatin (1 mg/kg) was administered intraperitoneally, followed by daily intraperitoneal injections of 5-fluorouracil (50 mg/kg) and calcium folinate (10 mg/kg) for 5 days. All solutions were freshly prepared in sterile saline before administration. The control group received an equivalent volume of saline via intraperitoneal injection. On the day of oxaliplatin injection, loperamide (0.2 mg/day) was administered via oral gavage to the designated mice, according to the experimental protocol. |
| Treatment Compound: | AOM, DSS, Loperamide, 5-fluorouracil, oxaliplatin, calcium folinate |
| Treatment Route: | Intraperitoneal injection/ gavage |
| Treatment Doseduration: | About three months |
| Treatment Vehicle: | normal saline |
| Animal Anesthesia: | Pentobarbital Sodium |
| Animal Acclimation Duration: | 2 weeks |
| Animal Fasting: | 12 hours before sacrifice |
| Animal Endp Euthanasia: | excessive anesthesia euthanasia |
Sample Preparation:
| Sampleprep ID: | SP004571 |
| Sampleprep Summary: | Metabolites Extraction of serum： 100 μL of serum was taken, mixed with 400 μL of extraction solution (MeOH:ACN, 1:1 (v/v)), the extraction solution contain deuterated internal standards, the mixed solution were vortexed for 30 s, sonicated for 10 min in 4 ℃ water bath, and incubated for 1 h at -40 ℃ to precipitate proteins. Then the samples were centrifuged at 12000 rpm (RCF=13800(×g),R= 8.6cm) for 15 min at 4 ℃. The supernatant was transferred to a fresh glass vial for analysis. The quality control (QC) sample was prepared by mixing an equal aliquot of the supernatant of samples. Metabolites Extraction of Solid： The animal tissue samples (25 mg±1 mg) were taken, mixed with beads and 500 μL of extraction solution (MeOH:ACN:H2O, 2:2:1 (v/v)). The extraction solution contain deuterated internal standards. The mixed solution were vortexed for 30 s. Then the mixed samples were homogenized (35 Hz,4 min) and sonicated for 5 min in 4 ℃ water bath, the step repeat for three times. The samples were incubated for 1 h at -40 ℃ to precipitate proteins. Then the samples ware centrifuged at 12000 rpm (RCF=13800(×g),R= 8.6cm) for 15 min at 4 ℃. The supernatant was transferred to a fresh glass vial for analysis. The quality control (QC) sample was prepared by mixing an equal aliquot of the supernatant of samples. |
| Processing Storage Conditions: | -80℃ |
| Extract Storage: | -80℃ |
Combined analysis:
| Analysis ID | AN007367 | AN007368 |
|---|---|---|
| Chromatography ID | CH005582 | CH005582 |
| MS ID | MS007061 | MS007062 |
| Analysis type | MS | MS |
| Chromatography type | HILIC | HILIC |
| Chromatography system | Thermo Vanquish | Thermo Vanquish |
| Column | Waters ACQUITY UPLC BEH Amide (50 x 2.1mm,1.7um) | Waters ACQUITY UPLC BEH Amide (50 x 2.1mm,1.7um) |
| MS Type | ESI | ESI |
| MS instrument type | Orbitrap | Orbitrap |
| MS instrument name | Thermo Orbitrap Exploris 120 | Thermo Orbitrap Exploris 120 |
| Ion Mode | POSITIVE | NEGATIVE |
| Units | peak area | peak area |
Chromatography:
| Chromatography ID: | CH005582 |
| Chromatography Summary: | For polar metabolites, LC-MS/MS analyses were performed using an UHPLC system (Vanquish, Thermo Fisher Scientific) with a Waters ACQUITY UPLC BEH Amide (2.1 mm × 50 mm, 1.7 μm) coupled to Orbitrap Exploris 120 mass spectrometer (Orbitrap MS, Thermo). The mobile phase consisted of 25 mmol/L ammonium acetate and 25 ammonia hydroxide in water（pH = 9.75）(A) and acetonitrile (B). The auto-sampler temperature was 4 ℃, and the injection volume was 2 μL. |
| Instrument Name: | Thermo Vanquish |
| Column Name: | Waters ACQUITY UPLC BEH Amide (50 x 2.1mm,1.7um) |
| Column Temperature: | 25 |
| Flow Gradient: | 0-0.25min, 95% B; 0.25-3.5min, 95%-65%B; 3.5-4min, 65%B-40%B; 4-4.5min, 40%B; 4.5-4.55min, 40%-95%B; 4.55-6min, 95%B |
| Flow Rate: | 0.5 mL/min |
| Injection Temperature: | 4 |
| Solvent A: | 100% water; 25mM ammonium acetate; 25mM ammonium hydroxide; pH = 9.75 |
| Solvent B: | 100% Acetonitrile |
| Chromatography Type: | HILIC |
MS:
| MS ID: | MS007061 |
| Analysis ID: | AN007367 |
| Instrument Name: | Thermo Orbitrap Exploris 120 |
| Instrument Type: | Orbitrap |
| MS Type: | ESI |
| MS Comments: | The Orbitrap Exploris 120 mass spectrometer was used for its ability to acquire MS/MS spectra on information-dependent acquisition (IDA) mode in the control of the acquisition software (Xcalibur, Thermo). In this mode, the acquisition software continuously evaluates the full scan MS spectrum. The ESI source conditions were set as following: sheath gas flow rate as 50 Arb, Aux gas flow rate as 15 Arb, capillary temperature 320 ℃, full MS resolution as 60000, MS/MS resolution as 15000, collision energy: SNCE 20/30/40, spray voltage as 3.8 kV (positive) |
| Ion Mode: | POSITIVE |
| MS ID: | MS007062 |
| Analysis ID: | AN007368 |
| Instrument Name: | Thermo Orbitrap Exploris 120 |
| Instrument Type: | Orbitrap |
| MS Type: | ESI |
| MS Comments: | The Orbitrap Exploris 120 mass spectrometer was used for its ability to acquire MS/MS spectra on information-dependent acquisition (IDA) mode in the control of the acquisition software (Xcalibur, Thermo). In this mode, the acquisition software continuously evaluates the full scan MS spectrum. The ESI source conditions were set as following: sheath gas flow rate as 50 Arb, Aux gas flow rate as 15 Arb, capillary temperature 320 ℃, full MS resolution as 60000, MS/MS resolution as 15000, collision energy: SNCE 20/30/40, spray voltage was -3.4 kV (negative). |
| Ion Mode: | NEGATIVE |
